invas
fungal
infect
ifi
repres
signific
caus
morbid
mortal
patient
undergo
allogen
hematopoiet
stem
cell
transplant
allosct
cumul
incid
provenprob
ifi
ppifi
rang
allosct
vari
accord
sever
risk
factor
donor
type
durat
neutropenia
occurr
graftversushost
diseas
gvhd
requir
system
steroid
treatment
object
tcellreplet
haploident
stem
cell
transplant
haplosct
posttranspl
cyclophosphamid
ptci
high
risk
invas
fungal
infect
ifi
antimoldact
drug
requir
primari
antifung
prophylaxi
pap
accord
intern
guidelin
data
avail
efficaci
caspofungin
pap
set
report
retrospect
experi
consecut
patient
treat
caspofungin
pap
haplosct
caspofungin
administ
preengraft
phase
result
hundredday
cumul
incid
provenprob
ifi
ppifi
median
day
onset
postsct
patient
die
ppifi
overal
surviv
os
nonrelaps
mortal
nrm
hazard
ratio
hr
patient
experienc
ifi
p
p
respect
threeyear
overal
surviv
os
nonrelaps
mortal
nrm
respect
univari
analysi
durat
neutropen
phase
partial
remiss
pretranspl
diseas
statu
associ
increas
incid
ifi
confirm
multivari
analysi
summari
pap
caspofungin
effect
strategi
prevent
ifi
context
haplosct
ptci
effort
requir
order
identifi
potent
strategi
abl
avoid
occurr
breakthrough
infect
caspofungin
haploident
stem
cell
transplant
primari
antifung
prophylaxi
among
risk
factor
ifi
donor
type
pretranspl
variabl
potenti
use
dictat
choic
primari
antifung
prophylaxi
pap
prospect
studi
transnet
databas
trapianto
midollo
osseo
gitmo
describ
incid
ppifi
approxim
twice
high
mismatch
relat
donor
mmrd
compar
match
relat
donor
mrd
smaller
retrospect
studi
compris
differ
type
haploident
transplant
platform
consist
found
higher
risk
ifi
haploidenticalmmrd
transplant
rel
mrd
allosct
antifung
prophylaxi
heterogen
studi
rang
fluconazol
antimoldact
agent
report
support
urgent
need
stringent
pap
haploident
transplant
order
reduc
occurr
ifi
ifirel
mortal
high
addit
epidemiolog
studi
fungal
infect
prophylaxi
last
year
shown
shift
candida
remain
second
major
caus
compris
albican
nonalbican
aspergillu
speci
frequent
agent
respons
ifi
allosct
given
background
gitmo
recommend
employ
antimold
prophylaxi
patient
higher
risk
ifi
base
donor
type
haploident
cord
blood
time
transplant
preor
postengraft
phase
occurr
gvhd
itraconazol
voriconazol
posaconazol
receiv
bibii
level
recommend
last
version
ecil
recommend
data
avail
either
recommend
contraind
echinocandin
pap
institut
aim
studi
analyz
efficaci
caspofungin
pap
term
ifi
incid
first
day
allosct
term
patient
longterm
outcom
retrospect
studi
compris
consecut
patient
hematolog
malign
receiv
tcellreplet
haplosct
ptci
institut
donor
defin
haploident
donor
recipi
hla
mismatch
share
one
haplotyp
transplant
strategi
base
baltimor
studi
donor
graft
manipul
tcellreplet
gvhd
prophylaxi
consist
cyclosporin
mycophenol
highdos
cyclophosphamid
patient
provid
inform
consent
retrospect
collect
data
studi
approv
institut
review
board
institut
three
main
condit
regimen
employ
nonmyeloabl
nma
regimen
compris
cy
mgkg
day
fludarabin
mgm
day
day
lowdos
total
bodi
irradi
tbi
gy
day
b
reduc
intens
ric
regimen
compris
either
thiotepa
mgkg
day
cyclophosphamid
mgkg
day
day
fludarabin
mgm
day
day
thiotepa
mgkg
day
busulfan
mg
kg
day
day
fludarabin
mgm
day
day
c
myeloabl
mac
condit
compris
thiotepa
mgkg
day
day
busulfan
mgkgdie
day
day
fludarabin
mgm
day
day
potenti
famili
member
type
hlaa
hlab
loci
high
level
resolut
select
donor
also
type
hlac
locu
highresolut
level
graft
sourc
repres
either
bone
marrow
bm
peripher
blood
stem
cell
pbsc
target
minimum
unmanipul
bm
peripher
blood
stem
cell
pbsc
use
stem
cell
support
day
graft
sourc
begin
mainli
repres
bone
marrow
baltimor
protocol
thereaft
pbsc
mainli
use
due
easier
collect
strategi
highdos
cyclophosphamid
mgkg
administ
day
day
transplant
cyclosporin
csa
dose
mgkg
continu
infus
discharg
convert
oral
formul
thereaft
csa
dosag
adjust
base
respect
rang
activ
ngml
mmf
administ
mgkg
po
three
time
per
day
day
csa
mmf
start
day
csa
taper
day
gcsf
start
day
patient
neutrophil
engraft
defin
first
three
consecut
day
absolut
neutrophil
count
anc
l
transplant
platelet
engraft
defin
platelet
count
l
transfus
preced
day
acut
gvhd
agvhd
grade
accord
keyston
criteria
chronic
gvhd
cgvhd
retrospect
grade
follow
nih
criteria
patient
alloc
hepafilt
room
begin
condit
neutrophil
engraft
receiv
low
microbi
diet
blood
vessel
access
cvc
place
patient
underw
microbiolog
surveil
includ
cultur
stool
urin
swab
anal
area
start
condit
weekli
discharg
case
fever
defin
temperatur
follow
exami
week
day
day
routin
screen
ifi
perform
transplant
possibleprobableproven
ifi
pppifi
ppifi
defin
accord
standard
intern
criteria
onset
pppand
ppifi
defin
day
first
posit
radiolog
examin
posit
cultur
patholog
test
pppand
ppifi
record
first
day
allosct
primari
endpoint
studi
investig
cumul
incid
ifi
infect
patient
receiv
pap
caspofungin
secondari
endpoint
longterm
outcom
paramet
overal
surviv
os
nonrelaps
mortal
nrm
categor
variabl
express
proport
continu
variabl
median
respect
rang
cumul
incid
agvhd
estim
consid
death
relat
agvhd
within
year
posttranspl
compet
event
cgvhd
estim
patient
aliv
day
consid
death
relat
cgvhd
within
year
posttranspl
compet
event
calcul
nrm
diseas
relaps
progress
treat
compet
event
wherea
nrm
compet
event
calcul
cumul
incid
relaps
progress
kaplanmei
method
use
os
progressionfre
surviv
pf
analys
outcom
respect
confid
interv
ci
calcul
date
transplant
comparison
group
made
logrank
gray
test
whenev
indic
cumul
incid
pppand
ppifi
day
estim
consid
death
reason
relat
ifi
infect
compet
event
univari
cox
regress
model
use
identifi
signific
moder
independ
covari
occurr
ppifi
ifi
treat
timevari
explanatori
covari
account
effect
os
nrm
hazard
ratio
hr
confid
interv
ci
report
hr
denot
unfavor
effect
p
valu
consid
signific
spss
version
ibm
armonk
ny
usa
ezr
easi
r
r
institut
statist
comput
vienna
austria
use
novemb
decemb
consecut
patient
receiv
haplosct
ptci
institut
treat
caspofungin
pap
patient
characterist
shown
tabl
median
age
main
underli
diagnos
repres
lymphoma
acut
myeloid
leukemia
condit
consist
mainli
ric
nma
regimen
fortyon
percent
patient
receiv
graft
bm
cell
pbsc
first
day
transplant
gitmo
earli
phase
patient
highrisk
categori
accord
gitmo
classif
mainli
treat
haplosct
plu
presenc
anoth
advers
variabl
prolong
neutropenia
recurr
cmv
infect
day
day
gitmo
late
phase
minor
case
highrisk
categori
mainli
due
acut
gvhd
requir
system
steroid
recurr
cmv
infect
diseas
first
day
posthaplosct
cumul
incid
pppifi
ci
case
figur
ppifi
occur
patient
cumul
incid
analyz
risk
factor
commonli
associ
fungal
infect
univari
analysi
found
tabl
longer
postsct
neutropen
phase
higher
chanc
experienc
ppifi
within
first
day
caspofungin
prophylaxi
limit
engraft
phase
ifi
occur
day
cumul
incid
perform
subanalysi
studi
whether
day
correl
gitmo
earlyphas
risk
categori
could
find
signific
differ
standard
risk
vs
high
risk
p
note
multivari
analysi
highveri
high
diseas
risk
index
dri
retain
independ
valu
increas
risk
ifi
hr
p
howev
confid
interv
wide
due
small
number
event
therefor
result
need
confirm
larger
number
patient
addit
compar
cumul
incid
ppifi
cohort
histor
group
patient
n
receiv
iv
itraconazol
pap
april
octob
institut
two
group
differ
patient
characterist
sinc
cohort
receiv
caspofungin
older
higher
frequenc
highrisk
hctci
previou
autolog
transplant
intens
condit
tabl
take
limit
consider
observ
trend
reduc
cumul
incid
ppifi
caspofungin
rel
itraconazol
prophylaxi
ci
vs
ci
figur
p
ninetyfour
patient
evalu
patient
die
engraft
experienc
graft
failur
median
time
anc
ml
day
rang
median
time
platelet
count
ml
rang
note
patient
neutropenia
last
day
median
followup
aliv
patient
tabl
report
diagnosi
pneumon
per
haplosct
ptci
higher
risk
mold
infect
rel
mrd
counterpart
found
cumul
incid
ppifi
compar
well
one
report
literatur
recipi
haplosct
past
year
tcellreplet
haplosct
gradual
intensifi
immunosuppress
regimen
describ
higher
incid
ifi
earli
phase
follow
late
one
baltimor
platform
cumul
incid
ppifi
vari
retrospect
studi
raiola
et
al
fluconazol
use
pap
haplosct
recipi
experienc
ppifi
aspergillu
frequent
agent
follow
candida
nonalbican
fusarium
speci
anoth
report
group
patient
receiv
fluconazol
minor
caspofungin
follow
itraconazol
cumul
incid
ppifi
recent
experi
report
micafungin
prophylaxi
yield
cumul
incid
ppifi
ta
b
l
e
continu
itraconazol
voriconazol
posaconazol
reduc
incid
ppifi
wherea
posaconazol
voriconazol
seem
superior
oral
itraconazol
order
reduc
incid
invas
aspergillosi
detail
cumul
incid
ppifi
low
phase
studi
rang
note
studi
includ
patient
receiv
match
relat
match
unrel
donor
therefor
well
known
efficaci
voriconazol
posaconazol
haplosct
set
accord
find
recent
updat
ecil
gitmo
german
australian
guidelin
group
patient
caspofungin
advers
pretranspl
featur
moreov
data
blood
concentr
itraconazol
avail
even
patient
receiv
iv
itraconazol
thu
reduc
risk
low
blood
level
frequent
observ
oral
formul
conclus
found
pap
caspofungin
preengraft
phase
result
manag
incid
ppifi
platform
haplosct
ptci
larger
prospect
studi
warrant
order
identifi
agent
may
reduc
cumul
incid
provenprob
ifi
context
haplosct
ptci
author
conflict
interest
disclos
jacopo
mariotti
http
